Boston Scientific Corporation reported net sales of USD 5.29 billion for the fourth quarter (Q4), an increase of 15.9 percent compared to the prior year period. For the full year (FY), net sales grew 19.9 percent to USD 14.66 billion. GAAP net income attributable to shareholders for Q4 was USD 0.45 per share, while adjusted earnings per share $(EPS)$ reached USD 0.80. For the full year, GAAP net income attributable to shareholders stood at USD 2.90 billion, or USD 1.94 per share, and adjusted EPS was USD 3.06. Segment performance in Q4 included MedSurg net sales growth of 11.7 percent. Boston Scientific’s chairman and CEO, Mike Mahoney, highlighted the company’s continued global innovation and high performance, citing the impact on millions of patient lives and a strong positioning for future growth. The company exceeded its full-year goals and noted ongoing dedication and consistency from its global teams. A conference call to discuss the results was scheduled, with a webcast available on the company’s investor website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein.